BETA-LACTAMASE-HEMMER

European patent · EP2928898 · In force

Register entry

Publication number
EP2928898
Application number
EP13861198
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 5, 2013
Published
Oct 14, 2015
Granted
Apr 14, 2021
Protection ends at the latest
Dec 4, 2033
Next annual fee due
Dec 31, 2026
IPC classes
A61K 31/69 (2006.01)
C07F 5/02 (2006.01)
A61K 45/06 (2006.01)
A61P 31/04 (2006.01)
Priority
US 201261734900 P 07.12.2012
US 201361783238 P 14.03.2013
PCT application
PCT/US2013/073428 05.12.2013
PCT publication
WO2014/089365 12.06.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 27, 2026

    Change

    Published in Swissreg on 27.05.2026

  2. Jan 9, 2025

    Change

    Published in Swissreg on 09.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Jan 10, 2023

    Change

    Published in Swissreg on 10.01.2023

  5. Feb 23, 2022

    Change

    Published in Swissreg on 23.02.2022

  6. Apr 14, 2021

    Granted

    Published in Swissreg on 14.04.2021

Parties

Holder

Venatorx Pharmaceuticals, Inc.

30 Spring Mill Drive, Malvern, PA 19355, US

Inventor

MCGARRY, Daniel

Exton, PA 19341, US

TROUT, Robert E. Lee

Bechtelsville, PA 19505, US

DAIGLE, Denis

Havre de Grace, MD 21078, US

PEVEAR, Daniel C.

Downingtown, PA 19335, US

LIU, Bin

Dayton, NJ 08810, US

BURNS, Christopher, J.

Malvern, PA 19355, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.